特利加压素治疗肝肾综合征的疗效分析  

Observation of terlipressin in management of patients with hepatorenal syndrome

作　　者：俞哲[1] 叶坚虹[1] 王琛[1] 茹仁萍[1] 

机构地区：[1]杭州市第六人民医院

出　　处：《中国临床药理学与治疗学》2009年第10期1164-1167,共4页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的:观察特利加压素治疗肝肾综合征的疗效。方法:60例患者分为2组,在内科综合治疗基础上,A组使用特利加压素,B组为对照组,观察患者临床表现、实验室指标、转归等。结果:A组较B组平均动脉压增高、尿量增多、血Cr降低,有效率增加,差异有统计学意义。结论:特利加压素对肝肾综合征的治疗安全、有效。AIM：To observe the effect of terlipressin in the management of patients with hepatorenal syndrome.METHODS：60 patients were divided into two groups.In Group A,terlipressine was used and Group B was control group.The clinical manifestation,laboratory examination,turnover were observed during treatment.RESULTS：Compared with Group B,the effective power,the mean arterial pressure and the total urine output were increased significantly,the serum creatinine level was decreased remarkably.CONCLUSION：Terlipressin is safe and effective on hepatorenal syndrome with minute adverse reaction.

关 键 词：肝肾综合征 特利加压素 血管活性药物 药物治疗 

分 类 号：R575[医药卫生—消化系统]